Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression.

Wei X, Xu M, Wei Y, Huang F, Zhao T, Li X, Feng R, Ye BH.

J Hematol Oncol. 2014 Apr 16;7:34. doi: 10.1186/1756-8722-7-34.

2.

Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma.

Frei E, Visco C, Xu-Monette ZY, Dirnhofer S, Dybkær K, Orazi A, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Go RS, Piris MA, Møller MB, Young KH, Tzankov A.

J Clin Pathol. 2013 Nov;66(11):956-61. doi: 10.1136/jclinpath-2013-201619. Epub 2013 Jun 17.

PMID:
23775435
3.

Diminishing prognostic role of preexisting diabetes mellitus for patients with diffuse large B-cell lymphoma in the rituximab era.

Lu HJ, Huang YC, Liu CY, Hung MH, Hu MH, Wu CY, Hong YC, Hsiao LT, Gau JP, Liu JH, Hsu HC, Chiou TJ, Tzeng CH, Yu YB.

Ann Hematol. 2013 Nov;92(11):1495-501. doi: 10.1007/s00277-013-1789-y. Epub 2013 May 28.

PMID:
23712292
4.

BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.

Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM, Greiner TC, Connors JM, Staudt LM, Rimsza L, Jaffe E, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Gascoyne RD, Armitage JO, Weisenburger DD, Chan WC.

Clin Cancer Res. 2011 Dec 15;17(24):7785-95. doi: 10.1158/1078-0432.CCR-11-0267. Epub 2011 Sep 20.

5.

Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.

Stefancikova L, Moulis M, Fabian P, Vasova I, Zedek F, Ravcukova B, Muzik J, Kuglik P, Vranova V, Falkova I, Hrabalkova R, Smardova J.

Int J Oncol. 2011 Dec;39(6):1413-20. doi: 10.3892/ijo.2011.1170. Epub 2011 Aug 18.

PMID:
21874232
6.

High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.

Li ZM, Huang JJ, Xia Y, Zhu YJ, Zhao W, Wei WX, Jiang WQ, Lin TY, Huang HQ, Guan ZZ.

Eur J Haematol. 2012 Jun;88(6):510-7. doi: 10.1111/j.1600-0609.2012.01778.x. Epub 2012 Mar 27.

PMID:
22413767
7.

Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP.

Huang X, Meng B, Iqbal J, Ding BB, Perry AM, Cao W, Smith LM, Bi C, Jiang C, Greiner TC, Weisenburger DD, Rimsza L, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Gascoyne RD, Cook JR, Tubbs RR, Jaffe ES, Armitage JO, Vose JM, Staudt LM, McKeithan TW, Chan WC, Ye BH, Fu K.

J Clin Oncol. 2013 Dec 20;31(36):4520-8. doi: 10.1200/JCO.2012.45.6004. Epub 2013 Nov 12.

8.

Matched-pair analysis comparing the outcomes of T cell/histiocyte-rich large B cell lymphoma and diffuse large B cell lymphoma in patients treated with rituximab-CHOP.

Kim YS, Ji JH, Ko YH, Kim SJ, Kim WS.

Acta Haematol. 2014;131(3):156-61. doi: 10.1159/000353787. Epub 2013 Oct 31.

PMID:
24192382
9.

Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era.

Zaky AH, Bakry R, El-sayed MI, Elwanis MA, Nabih O.

Hematology. 2014 Oct;19(7):412-6. doi: 10.1179/1607845413Y.0000000147. Epub 2014 Jan 20.

PMID:
24620947
10.

Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone.

Hui D, Proctor B, Donaldson J, Shenkier T, Hoskins P, Klasa R, Savage K, Chhanabhai M, Gascoyne RD, Connors JM, Sehn LH.

Leuk Lymphoma. 2010 Sep;51(9):1658-67. doi: 10.3109/10428194.2010.504872.

PMID:
20795790
11.

Survival of patients with transformed lymphoma in the rituximab era.

Guirguis HR, Cheung MC, Piliotis E, Spaner D, Berinstein NL, Imrie K, Zhang L, Buckstein R.

Ann Hematol. 2014 Jun;93(6):1007-14. doi: 10.1007/s00277-013-1991-y. Epub 2014 Jan 11.

PMID:
24414374
12.

Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.

Avivi I, Zilberlicht A, Dann EJ, Leiba R, Faibish T, Rowe JM, Bar-Shalom R.

Am J Hematol. 2013 May;88(5):400-5. doi: 10.1002/ajh.23423. Epub 2013 Mar 19.

13.

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.

Li X, Liu Z, Cao J, Hong X, Wang J, Chen F, Wang C, Zou S, Li J, Shen Z.

Ann Hematol. 2012 Jun;91(6):837-45. doi: 10.1007/s00277-011-1375-0. Epub 2011 Dec 9.

PMID:
22160255
14.

Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.

Merli F, Luminari S, Rossi G, Mammi C, Marcheselli L, Tucci A, Ilariucci F, Chiappella A, Musso M, Di Rocco A, Stelitano C, Alvarez I, Baldini L, Mazza P, Salvi F, Arcari A, Fragasso A, Gobbi PG, Liberati AM, Federico M.

Leuk Lymphoma. 2012 Apr;53(4):581-8. doi: 10.3109/10428194.2011.621565. Epub 2011 Nov 15.

PMID:
21895543
15.

Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older.

Meguro A, Ozaki K, Sato K, Oh I, Fujiwara S, Hosonuma R, Sasazaki M, Kikuchi Y, Hirata Y, Yamamoto C, Uesawa M, Kobayashi H, Matsu H, Okabe H, Uehara E, Nishikawa A, Tatara R, Hatano K, Yamamoto C, Matsuyama T, Toshima M, Ueda M, Ohmine K, Suzuki T, Mori M, Nagai T, Muroi K, Ozawa K.

Leuk Lymphoma. 2012 Jan;53(1):43-9. doi: 10.3109/10428194.2011.600486. Epub 2011 Aug 24.

PMID:
21864040
17.

Prognostic significance of survivin and caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP.

Mitrović Z, Ilić I, Aurer I, Kinda SB, Radman I, Dotlić S, Ajduković R, Labar B.

Pathol Oncol Res. 2011 Jun;17(2):243-7. doi: 10.1007/s12253-010-9304-4. Epub 2010 Sep 18.

PMID:
20853074
18.

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.

Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A.

Lancet Oncol. 2013 May;14(6):525-33. doi: 10.1016/S1470-2045(13)70122-0. Epub 2013 Apr 9.

PMID:
23578722
19.

Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era.

Dalia S, Chavez J, Little B, Bello C, Fisher K, Lee JH, Chervenick P, Sokol L, Sotomayor E, Shah B.

Ann Hematol. 2014 Aug;93(8):1305-12. doi: 10.1007/s00277-014-2031-2. Epub 2014 Mar 4.

PMID:
24590536
20.

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.

Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, Belch A, Walewski J, Zinzani PL, Mingrone W, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Corrado C, Scheliga A, Loeffler M, Kuhnt E; MabThera International Trial (MInT) Group.

Lancet Oncol. 2008 May;9(5):435-44. doi: 10.1016/S1470-2045(08)70078-0. Epub 2008 Apr 8.

PMID:
18400558

Supplemental Content

Support Center